| Total (n = 2448) | Criteria = 1 (n = 1520) | Criteria> = 2 (n = 928) | p‐Value | |
|---|---|---|---|---|
| Age [years], mean (SD) | 75.0 ± 8.3 | 72.7 ± 8.4 | 78.9 ± 6.6 | <0.001 |
| Gender, male (%) | 801 (32.7) | 542 (35.7) | 259 (27.9) | <0.001 |
| Body weight [kg], mean (SD) | 55.4 ± 8.2 | 57.7 ± 8.4 | 51.7 ± 6.1 | <0.001 |
| BMI, mean (SD) | 22.9 ± 3.0 | 23.5 ± 3.0 | 21.9 ± 2.7 | <0.001 |
| CrCl [mL/min], mean (SD) | 51.4 ± 18.8 | 59.1 ± 18.5 | 39.1 ± 11.3 | <0.001 |
| CHA2DS2‐VASc, mean (SD) | 3.7 ± 1.5 | 3.4 ± 1.4 | 4.2 ± 1.4 | <0.001 |
| HAS‐BLED, mean (SD) | 2.1 ± 1.0 | 2.0 ± 1.0 | 2.3 ± 1.0 | <0.001 |
| Medical history, n (%) | ||||
| Hypertension | 1757 (71.8) | 1070 (70.4) | 687 (74.0) | 0.053 |
| Stroke | 272 (11.1) | 144 (9.5) | 128 (13.8) | 0.001 |
| Diabetes | 649 (26.5) | 387 (25.5) | 262 (28.2) | 0.143 |
| Heart failure | 647 (26.4) | 342 (22.5) | 305 (32.9) | <0.001 |
| Dose reduction criteria, n (%) | ||||
| Body weight ≤ 60 kg | 2095 (85.6) | 1170 (77.0) | 925 (99.7) | <0.001 |
| CrCl 15–50 mL/min | 1171 (47.8) | 284 (18.7) | 887 (95.6) | <0.001 |
| Concomitant use of P‐gp inhibitors | 128 (5.2) | 66 (4.3) | 62 (6.7) | 0.015 |
| Number of dose reduction criteria = 1 | 1520 (62.1) | |||
| Number of dose reduction criteria = 2 | 914 (37.3) | |||
| Number of dose reduction criteria = 3 | 14 (0.6) |
BMI: body mass index, CrCl: creatinine clearance, P‐gp: P‐glycoprotein.